ctDNA Analysis and Relapse Association in Primary RRMM Patients Presented at ASCO 2022

Dr. Sridurga Mithraprabhu Discusses ctDNA Analysis and Relapse Association in Primary RRMM Patients Receiving Secondary Salvage Therapy

Abstract Title:

Circulating tumor DNA analysis and association with relapse in patients with primary refractory multiple myeloma receiving secondary salvage therapy.

What is the purpose of this trial? 

Multiple myeloma (MM) is an incurable plasma cell malignancy with a 5 year-median overall survival (OS) in newly diagnosed (ND) patients. Currently, identifying high-risk patients is impossible. Genomic studies could potentially inform alternative secondary therapeutic options. Circulating tumor DNA (ctDNA) analysis could provide a more holistic approach to determine genomics of high-risk patients than bone marrow (BM) tumor DNA analysis in this genetically heterogenous multi-site malignancy.

In this video:

Dr. Sridurga Mithraprabhu (Alfred Hospital / Monash University—Melbourne, Australia) discusses circulating tumor DNA (ctDNA) analysis and relapse association in primary relapsed/refractory multiple myeloma (RRMM) patients receiving secondary salvage therapy. 

Conclusion:

Analysis shows that RAS/RAF and ATM/ATR/TP53 mutations in circulating tumor DNA (ctDNA) could be prognostic biomarkers of response to secondary salvage therapy in primary refractory patients thus, providing the opportunity to design targeted salvage treatment paradigms in high-risk multiple myeloma (HRMM) patients.